(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000688 A1

(51) International Patent Classification[7]: C07D 471/04, 487/04, A61K 31/437, 31/4985, A61P 29/00, 11/00, 9/00, 35/00 // (C07D 471/04, 221:00, 209:00) (C07D 487/04, 241:00, 209:00)

(21) International Application Number: PCT/GB02/02799

(22) International Filing Date: 20 June 2002 (20.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0115109.1	21 June 2001 (21.06.2001)	GB
60/300,257	22 June 2001 (22.06.2001)	US


(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMA LIMITED** [GB/GB]; Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COX, Paul, Joseph** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **MAJID, Tahir, Nadeem** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **LAI, Justine, Yeun, Quai** [SG/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **MORLEY, Andrew** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **AMENDOLA, Shelley** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **DE-PRETS, Stephanie, Daniele** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **EDLIN, Chris** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **GARDNER, Charles, J.** [US/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **KOMINOS, Dorothea** [US/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **PEDGRIFT, Brian, Leslie** [GB/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **HALLEY, Frank** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **GILLESPY, Timothy, Alan** [US/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **EDWARDS, Michael** [US/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **CLERC, Francois, Frederic** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **NEMECEK, Conception** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **HOUILLE, Olivier** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **DAMOUR, Dominique** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **BOUCHARD, Hervé** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **BEZARD, Daniel** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). **CARREZ, Chantal** [FR/GB]; Aventis Pharma Limited, Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB).

[Continued on next page]

(54) Title: AZAINDOLES



(I)

(57) Abstract: The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

WO 03/000688 A1

(74) **Agent: JONES, Stephen, Anthony**; Adamson Jones, Broadway Business Centre, 32a Stoney Street, Nottingham NG1 1LL (GB).

(81) **Designated States** *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.